



FOR IMMEDIATE RELEASE

## **Cato Research awarded “Best International Clinical Trial Services Provider 2018”**

Durham, NC, 23 March 2018 — [Cato Research \(CATO\)](http://www.cato.com) was awarded “Best International Clinical Trial Services Provider 2018” by Global Health & Pharma (GHP). GHP announced winners today, recognizing key players and companies within the ever evolving and ground-breaking industry of drug research and development.

“The awards are given solely on merit and are awarded to commend those most deserving for their ingenuity and hard work, distinguishing them from their competitors and proving them worthy of recognition.,” states GHP.

Lynda Sutton, Cofounder and President of Cato Research commented: “Cato Research is honored to accept this award as it truly highlights our efforts and quality in clinical trial operations, especially international clinical trial work.”

### **About Cato Research**

Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, North Carolina, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of approximately 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients’ products to market with speed and cost effectiveness. For more information about Cato Research, visit [www.cato.com](http://www.cato.com).

### **About Cato BioVentures**

Cato BioVentures is the venture capital affiliate of Cato Research, a global contract research and development organization (CRO). For over 30 years, Cato BioVentures and Cato Research have partnered with entrepreneurs, academic institutions, and a broad base of biotechnology and pharmaceutical companies to advance a robust

#### **CATO STRATEGIC LOCATIONS**

**Durham, North Carolina, USA +1-919-361-2286 [www.CATO.com](http://www.CATO.com)**

Montreal, Canada  
Tallinn, Estonia  
Cologne, Germany

Frankfurt am Main, Germany  
Riga, Latvia  
Vilnius, Lithuania

Belgrade, Serbia  
Tel Aviv, Israel  
Johannesburg, South Africa

Boston, Massachusetts, USA  
San Diego, California, USA  
Washington, D.C., USA



Westpark Corporate Center  
4364 South Alston Avenue  
Durham, NC 27713-2220 USA  
Phone: 919-361-2286  
Fax: 919-361-2290  
[www.cato.com](http://www.cato.com)

portfolio of successful product development programs. Through strategic CRO service agreements with Cato Research, Cato BioVentures has invested its CRO Service Capital™ in innovative therapeutics, medical devices, and stem cell technologies that improve the pharmaceutical industry's research and development productivity. If strategic outsourcing for development, regulatory, and clinical support is a core component of a company's business plan, then Cato BioVenture's investment model can make a positive difference in the company's overall success. For more information about Cato BioVentures, call 919-361-2286 or visit [www.catobioventures.com](http://www.catobioventures.com).

For more information, please contact:

Cato Research  
Phone: 919-361-2286  
[www.cato.com](http://www.cato.com)

# # #